This top Canadian pot company is arguably missing one key piece that could transform it into a bona fide wealth escalator for early investors.
These two biotech stocks are poised for big gains next year.
BioMarin Pharmaceutical and Vertex Pharmaceuticals should prove to be outstanding growth vehicles in 2020 and beyond.
Should Aphria's clearance-rack valuation tempt bargain hunters?
The beaten-down pot industry is getting much-needed relief from Cannabis 2.0.
Alexion Pharmaceuticals will reportedly buy clinical-stage rival Achillion Pharmaceuticals in an all-cash deal.
Which of these NASH-oriented biotechs is the better buy?
Aurora's stock may make you rich -- but there's one big caveat.
Bargain hunters should continue to avoid HEXO's stock.
HEXO's preliminary revenue figures for its fiscal fourth quarter aren't sitting well with investors today.
Which of these top pot stocks is the better buy right now?
Which of these two biotech titans is the better buy right now?
These three beaten-down cancer stocks could prove to be amazing value plays.
A short-seller report weighed on the Chinese biotech's shares last month.
AbbVie's shares reversed course last month. Here's why.
The competitive outlook for a key therapy is worrying investors.
Which of these pot titans is the better buy?
Aphria and Charlotte's Web Holdings are both outstanding long-term growth vehicles. Here's why.
AbbVie and Amgen are two great stocks that are way too cheap right now.
These small-cap healthcare stocks are definitely worth checking out this month.